# Impact of prognostic nutritional index and geriatric nutritional risk index on prognosis in elderly patients with early-stage prostate cancer

**Authors:** Pinar Peker, Asli Geçgel, Oǧuzcan Özkan, Serdar Yilmaz, Seher Selvi, Cafer Cirik, Sezen Koca, Alpay Düşgün, Burcu Arslan Benli, Berna Bozkurt Duman, Timuçin Çil

PMC · DOI: 10.3389/fnut.2026.1745718 · Frontiers in Nutrition · 2026-02-17

## TL;DR

This study shows that nutritional and inflammatory indicators like PNI and GNRI can predict survival in elderly patients with early-stage prostate cancer.

## Contribution

The study demonstrates that PNI and GNRI are independent prognostic factors in elderly early-stage prostate cancer patients.

## Key findings

- Low PNI and GNRI were associated with significantly shorter overall survival in patients.
- Higher Gleason score, higher PSA, and older age were also linked to worse outcomes.
- Radiotherapy improved survival compared to non-radiotherapy treatments.

## Abstract

Prostate cancer predominantly affects older men and generally has a favorable early-stage prognosis, yet the prognostic significance of nutritional and inflammatory status remains uncertain. This study evaluated the prognostic value of the Prognostic Nutritional Index (PNI) and Geriatric Nutritional Risk Index (GNRI) in elderly patients with localized prostate cancer.

This single-center retrospective cohort study included 205 patients aged ≥65 years with early-stage prostate cancer treated between 2018 and 2024. Nutritional status was assessed at baseline using serum albumin, lymphocyte count, and body weight to calculate the PNI and GNRI. Overall survival was analyzed using standard survival analysis methods. All statistical analyses were performed using SPSS software version 26.0.

The median patient age was 72 years. Of all patients, 41% were 75 years or older. Survival analysis showed that patients with low PNI had a median OS of 78 months. Those with high PNI had a median OS of 115 months (p = 0.008). Low GNRI was linked to a median survival of 74 months. High GNRI was linked to 120 months (p = 0.009). Higher Gleason score (≥8), higher PSA (≥10 ng/mL), older age (≥75 years), and clinical T2 disease were associated with worse outcomes. By contrast, radiotherapy improved survival (122 vs. 94 months, p = 0.008). In multivariate analysis, low PNI, low GNRI, high Gleason score, and high PSA remained independent predictors.

The PNI and GNRI serve as practical and accessible indicators of nutritional status and inflammation, thereby improving prognostic assessment and risk stratification in older patients with early-stage prostate cancer.

## Linked entities

- **Diseases:** prostate cancer (MONDO:0005159)

## Full-text entities

- **Genes:** KLK3 (kallikrein related peptidase 3) [NCBI Gene 354] {aka APS, KLK2A1, PSA, hK3}, NT5C3A (5'-nucleotidase, cytosolic IIIA) [NCBI Gene 51251] {aka CNSHA8, NT5C3, P5'N-1, P5N-1, PN-I, POMP}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, NPEPPS (aminopeptidase puromycin sensitive) [NCBI Gene 9520] {aka AAP-S, MP100, PSA}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, HP (haptoglobin) [NCBI Gene 3240] {aka HP2ALPHA2, HPA1S}, AR (androgen receptor) [NCBI Gene 367] {aka AIS, AR8, DHTR, HPCX3, HUMARA, HYSP1}
- **Diseases:** adiposity (MESH:D018205), acinar adenocarcinoma (MESH:D018267), systemic (MESH:D015619), postoperative (MESH:D019106), immune dysregulation (OMIM:614878), renal cell carcinoma (MESH:D002292), hypertension (MESH:D006973), death (MESH:D003643), GNRI (MESH:D044342), toxicity (MESH:D064420), gastric cancer (MESH:D013274), overweight (MESH:D050177), protein-energy malnutrition (MESH:D011502), T2 disease (MESH:C535434), cachexia (MESH:D002100), metabolic dysregulation (MESH:D021081), Frailty (MESH:D000073496), nutritional impairment (MESH:D009748), non-small cell lung cancer (MESH:D002289), Gleason 4+3 (MESH:D053307), loss of skeletal muscle mass (MESH:C536030), PCa (MESH:D011471), NLR (MESH:D015467), Sarcopenia (MESH:D055948), inflammation (MESH:D007249), small cell lung cancer (MESH:D055752), diabetes mellitus (MESH:D003920), cancer (MESH:D009369), AD (MESH:D000544), gastrointestinal, lung, and pancreatic cancers (MESH:D008175)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12953100/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12953100/full.md

## References

46 references — full list in the complete paper: https://tomesphere.com/paper/PMC12953100/full.md

---
Source: https://tomesphere.com/paper/PMC12953100